8384 Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices 

Form/OMB No.: 0990–

Use: The ‘‘Understanding Barriers and 

Successful Strategies for Faith-Based 

Organizations in Accessing Grants’’

study aims to complement internal 

Health and Human Services (HHS) 

efforts to provide equal access to federal 

discretionary grants for faith-based 

organizations by collecting information 

directly from such organizations on 

their experiences applying for federal 

grants. 

Frequency: Single time. 

Affected Public: Not-for-profit 

institutions. 

Annual Number of Respondents: 290. 

Total Annual Responses: 290. 

Average Burden per Response: 35.3 

minutes. 

Total Annual Hours: 170. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, e-mail your request, 

including your address, phone number, 

OMB number, and OS document 

identifier, to 

Sherette.funncoleman@hhs.gov, or call 

the Reports Clearance Office on (202) 

690–6162. Written comments and 

recommendations for the proposed 

information collections must be 

received with 60 days, and directed to 

the OS Paperwork Clearance Officer at 

the following address: Department of 

Health and Human Services, Office of 

the Secretary, Assistant Secretary for 

Resources and Technology, Office of 

Resources Management, Attention: 

Sherrette Funn-Coleman (0990–NEW), 

Room 537–H, 200 Independence 

Avenue, SW., Washington, DC 20201. 

Dated: February 15, 2007. 

Alice Bettencourt, 

Office of the Secretary, Paperwork Reduction 

Act Reports Clearance Officer. 

[FR Doc. E7–3175 Filed 2–23–07; 8:45 am] 

BILLING CODE 4154–07–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

[Document Identifier: OS–0990–0243] [60- 

day notice] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Office of the Secretary, HHS. 

In compliance with the requirement 

of section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Office of the Secretary (OS), Department 

of Health and Human Services, is 

publishing the following summary of a 

proposed collection for public 

comment. Interested persons are invited 

to send comments regarding this burden 

estimate or any other aspect of this 

collection of information, including any 

of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

Type of Information Collection 

Request: Extension. 

Title of Information Collection: OCR 

Pre-grant Data Request Form. 

Form/OMB No.: 0990–0243. 

Use: The form is designed to collect 

data from health care providers who 

have requested certification to 

participate in the Medicare program. 

This civil rights compliance 

determination is an essential component 

of HHS’ decision to grant or deny 

certification and must be made prior to 

the Department’s final notification of its 

decision to the provider. 

Frequency: Recordkeeping single 

time. 

Affected Public: Business or other forprofit. 

Annual Number of Respondents: 

3,500. 

Total Annual Responses: 3,500. 

Average Burden per Response: 15 

hours. 

Total Annual Hours: 52,500. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, e-mail your request, 

including your address, phone number, 

OMB number, and OS document 

identifier, to 

Sherette.funncoleman@hhs.gov, or call 

the Reports Clearance Office on (202) 

690–6162. Written comments and 

recommendations for the proposed 

information collections must be 

received with 60-days, and directed to 

the OS Paperwork Clearance Officer at 

the following address: Department of 

Health and Human Services, Office of 

the Secretary, Assistant Secretary for 

Resources and Technology, Office of 

Resources Management, Attention: 

Sherrette Funn-Coleman (0990–0243), 

Room 537–H, 200 Independence 

Avenue, SW., Washington DC 20201. 

Dated: February 15, 2007. 

Alice Bettencourt, 

Office of the Secretary, Paperwork Reduction 

Act Reports Clearance Officer. 

[FR Doc. E7–3177 Filed 2–23–07; 8:45 am] 

BILLING CODE 4153–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Toxicology Program (NTP); 

Center for the Evaluation of Risks to 

Human Reproduction (CERHR); 

Announcement of the Availability of 

the Hydroxyurea Expert Panel Report; 

Request for Public Comment 

AGENCY: National Institute of 

Environmental Health Sciences; 

National Institutes of Health, HHS. 

ACTION: Request for comment. 

SUMMARY: CERHR announces 

availability of the hydroxyurea expert 

panel report by March 5, 2007 on the 

CERHR Web site (http:// 

cerhr.niehs.nih.gov) or in print from 

CERHR (see ‘‘ADDRESSES’’ below). This 

expert panel report is an evaluation of 

the reproductive and developmental 

toxicity of hydroxyurea conducted by a 

13-member expert panel composed of 

scientists from the Federal Government, 

universities, and private organizations. 

CERHR invites the submission of public 

comments on this expert panel report. 

DATES: The final hydroxyurea expert 

panel report will be available by March 

5, 2007, and written public comments 

on this report should be received by 

April 18, 2007. 

ADDRESSES: Public comments and any 

other correspondence should be sent to 

Dr. Michael D. Shelby, CERHR Director, 

NIEHS, P.O. Box 12233, MD EC–32, 

Research Triangle Park, NC 27709 

(mail), (919) 316–4511 (fax), or 

shelby@niehs.nih.gov (e-mail). Courier 

address: CERHR, 79 T.W. Alexander 

Drive, Building 4401, Room 103, 

Research Triangle Park, NC 27709. 

SUPPLEMENTARY INFORMATION: 

Background 

Hydroxyurea is used in the treatment 

of cancer, sickle cell disease, and 

thalassemia. It is the only treatment for 

sickle cell disease used in children 

aside from blood transfusion. 

Hydroxyurea may be used in the 

treatment of children and adults with 

sickle cell disease for an extended 

period of time or for repeated cycles of 

therapy. Treatment with hydroxyurea 

may be associated with cytotoxic and 

myelosuppressive effects and 

hydroxyurea is mutagenic. Hydroxyurea 

is FDA-approved for reducing the 

frequency of painful crises and the need 

for blood transfusions in adults with 

sickle cell anemia who experience 

recurrent moderate to severe crises. 

CERHR selected hydroxyurea for expert 

panel evaluation because of (1) 

increasing use in the treatment of sickle 

cell disease in children and adults, (2) 


ycherry on PROD1PC64 with NOTICES
Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices 8385 

knowledge that it inhibits DNA 

synthesis and is cytotoxic, and (3) 

published evidence of reproductive and 

developmental toxicity in rodents. 

The CERHR convened an expert panel 

on January 24–26, 2007, to review and 

revise the draft expert panel report and 

reach conclusions regarding whether 

exposure to hydroxyurea is a hazard to 

human development or reproduction. 

The expert panel also identified data 

gaps and research needs. Prior to the 

meeting, CERHR solicited public 

comment on the draft expert panel 

report (Federal Register Vol. 71, No. 199 

pp. 60746–60748). 

Following receipt of public comments 

on the hydroxyurea expert panel report, 

CERHR staff will prepare the NTP–

CERHR monograph. NTP–CERHR 

monographs are divided into four major 

sections: (1) The NTP Brief which 

provides the NTP’s interpretation of the 

potential for the chemical to cause 

adverse reproductive and/or 

developmental effects in exposed 

humans, (2) a roster of expert panel 

members, (3) the final expert panel 

report, and (4) public comments 

received on that report. The NTP Brief 

is based on the expert panel report, 

public comments on that report, public 

and peer review comments on the draft 

NTP Brief, and any new information 

that became available after the expert 

panel meeting. 

Request for Comments 

CERHR invites written public 

comments on the hydroxyurea expert 

panel report. Written comments should 

be sent to Dr. Michael Shelby at the 

address provided above. Persons 

submitting written comments are asked 

to include their name and contact 

information (affiliation, mailing address, 

telephone and facsimile numbers, email, and sponsoring organization, if 

any). All comments received will be 

posted on the CERHR website and will 

be included in the NTP–CERHR 

monograph on hydroxyurea. The NTP 

will consider all public comments 

during preparation of the NTP Brief. 

Background Information on CERHR 

The NTP established CERHR in June 

1998 [Federal Register, December 14, 

1998 (Vol. 63, No. 239, pp. 68782)]. 

CERHR is a publicly accessible resource 

for information about adverse 

reproductive and/or developmental 

health effects associated with exposure 

to environmental and/or occupational 

exposures. Expert panels conduct 

scientific evaluations of agents selected 

by CERHR in public forums. 

CERHR invites the nomination of 

agents for review or scientists for its 

expert registry. Information about 

CERHR and the nomination process can 

be obtained from its Web site (http:// 

cerhr.niehs.nih.gov) or by contacting Dr. 

Shelby (see ADDRESSES above). CERHR 

selects chemicals for evaluation based 

upon several factors including 

production volume, potential for human 

exposure from use and occurrence in 

the environment, extent of public 

concern, and extent of data from 

reproductive and developmental 

toxicity studies. 

CERHR follows a formal, multi-step 

process for review and evaluation of 

selected chemicals. The formal 

evaluation process was published in the 

Federal Register notice July 16, 2001 

(Vol. 66, No. 136, pp 37047–37048) and 

is available on the CERHR Web site 

under ‘‘About CERHR’’ or in printed 

copy from CERHR. 

Dated: February 12, 2007. 

Samuel H. Wilson, 

Deputy Director, National Institute of 

Environmental Health Sciences and National 

Toxicology Program. 

[FR Doc. E7–3151 Filed 2–23–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–07–0274] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Joan Karr, CDC 

Acting Reports Clearance Officer, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

CDC Model Performance Evaluation 

Program (MPEP) (0920–0274)—

Revision—National Center for 

Preparedness, Detection, and Control of 

Infectious Diseases (proposed) 

(NCPDCID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

CDC is requesting OMB approval of a 

revision to its data collection, the CDC 

Model Performance Evaluation Program 

(MPEP). CDC originally implemented 

MPEP in 1986 to evaluate the 

performance of laboratories conducting 

testing to detect human 

immunodeficiency virus type 1 (HIV–1) 

antibody (Ab). CDC is requesting a 3- 

year approval for this data collection. 

In this program, respondents receive 2 

shipments of specimens per year. 

Respondents test the specimens in their 

laboratory/testing site and report their 

results either using a report booklet or 

on-line. CDC provides the respondent 

with a report containing the analysis of 

the laboratory test results reported to 

CDC. Participation in this program is 

voluntary and provides the respondents 

an opportunity to (1) assure accurate 

tests are being provided by the 

laboratory/testing site through external 

quality assessment; (2) improve testing 

quality through self-evaluation in a 

nonregulatory environment; (3) test well 

characterized samples from a source 

outside the test kit manufacturer; (4) 

discover potential testing problems so 

that procedures can be adjusted to 

eliminate them; (5) compare of testing 

results with others at a national and 

international level; and (6) consult with 

CDC staff to discuss testing issues. 

In this request, CDC proposes to make 

the following revisions to the currently 

approved data collection: 

• Addition of a Name and Address 

change form to report changes for the 

MPEP manager and coordinator at the 

respondent laboratory; 

• Inclusion of additional test kit 

manufacturers approved by the FDA 

since previous OMB approval; and 

• Elimination of reporting HIV–1 

RNA Viral Load and CD4+ T-cell 

determinations. 

All respondents are MPEP affiliated 

laboratories. 


ycherry on PROD1PC64 with NOTICES